Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 47-51

  Hyacinth, Hyacinth I ^a,b   Adams, Robert J ^a   Voeks, Jenifer H ^a   Hibbert, Jacqueline M ^b   Gee, Beatrice E ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CATHEPSIN D; GLYCOPROTEIN; HEMOGLOBIN; IMMOBILIZED ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; NERVE CELL ADHESION MOLECULE 1; NEUROTROPIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RANTES; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ARTICLE; BLOOD CLOTTING; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SICKLE CELL ANEMIA; THROMBOGENICITY; THROMBOSIS; VASCULAR ENDOTHELIUM;

ADOLESCENT; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ENDOTHELIUM, VASCULAR; ERYTHROCYTE TRANSFUSION; HUMANS; RISK; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84892900299     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23586     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Children with sickle cell disease had significantly higher medical costs than those without sickle cell disease. Atlanta: Centers for disease Control and Prevention; 2012.
2. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prevent Med 2010;38:S512-S521.
3. Smith LA, Oyeku SO, Homer C, et al. Sickle cell disease: A question of equity and quality. Pediatrics 2006;117:1763-1770.
4. Weatherall DJ. Hemoglobinopathies worldwide: Present and future. Curr Mol Med 2008;8:592-599.
5. Pauling L, Itano HA. Sickle cell anemia a molecular disease. Science (New York, NY) 1949;110:543-548.
6. Noubouossie DF, Lê PQ, Corazza F, et al. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol 2012;87:145-149.
7. Hibbert JM, Hsu LL, Bhathena SJ, et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. Exp Biol Med 2005;230:68-74.
8. Driss A, Asare KO, Hibbert JM, et al. Sickle cell disease in the post genomic era: A monogenic disease with a polygenic phenotype. Genom Insights 2009;2:23-48.
9. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998;91:288-294.
10. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-610.
11. Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol 2012;157:14-25.
12. Hoppe C. Defining stroke risk in children with sickle cell anaemia. Br J Haematol 2005;128:751-766.
13. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: A predictive factor for recurrent cerebrovascular events. Blood 2002;99:3144-3150.
14. Gebreyohanns M, Adams RJ. Sickle cell disease: Primary stroke prevention. CNS Spectrum 2004;9:445-449.
15. Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 2006;149:710-712.
16. Deane CR, Goss D, Bartram J, et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica 2010;95:1287-1292.
17. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
18. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012;119:3925-3932.
19. Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-2778.
20. Kwiatkowski JL, Cohen AR, Garro J, et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol 2012;87:221-223.
21. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011;117:772-779.
22. Asare K, Gee BE, Stiles JK, et al. Plasma interleukin-1β concentration is associated with stroke in sickle cell disease. Cytokine 2010;49:39-44.
23. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84:618-625.
24. Merkel K, Ginsberg P, Parker J, et al. Cerebrovascular disease in sickle cell anemia: A clinical, pathological and radiological correlation. Stroke 1978;9:45-52.
25. Prohovnik I, Hurlet-Jensen A, Adams R, et al. Hemodynamic etiology of elevated flow velocity and stroke in sickle-cell disease. J Cereb Blood Flow Metab 2009;29:803-810.
26. Prohovnik I, Pavlakis SG, Piomelli S, et al. Cerebral hyperemia, stroke, and transfusion in sickle cell disease. Neurology 1989;39:344.
27. Lezcano NE, Odo N, Kutlar A, et al. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006;37:1424-1426.
28. Hyacinth HI, Gee BE, Adamkiewicz TV, et al. Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia. Cytokine 2012;60:302-308.
29. Weyrich AS, Prescott SM, Zimmerman GA. Platelets, endothelial cells, inflammatory chemokines, and restenosis: Complex signaling in the vascular play book. Circulation 2002;106:1433-1435.
30. Jin C, Lu L, Zhu ZB, et al. Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation. Coron Artery Dis 2010;21:273-277.
31. Axell MZ, Zlateva S, Curtis M. A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells. J Neurosci Methods 2009;184:275-284.
32. Hayashi T, Seki T, Sato K, et al. Expression of polysialylated neural cell adhesion molecule in rat brain after transient middle cerebral artery occlusion. Brain Res 2001;907:130-133.
33. Nur E, Kim Y-S, Truijen J, et al. Cerebrovascular reserve capacity is impaired in patients with sickle cell disease. Blood 2009;114:3473-3478.
34. Briozzo P, Badet J, Capony F, et al. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: A permissive role of cathepsin D. Exp Cell Res 1991;194:252-259.
35. González V, Garijo, Fernández, et al. Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma. Histopathology 1999;34:35-42.
36. Urner M, Herrmann IK, Buddeberg F, et al. Effects of blood products on inflammatory response in endothelial cells in vitro. PLoS One 2012;7:e33403.
37. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004;11:129-151.
38. Dowling MM, Quinn CT, Plumb P, et al. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood 2012;120:3891-3897.
39. Ataga KI, Brittain JE, Desai P, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One 2012;7:e29786.